Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy

Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Moretti, Davide Vito, Binetti, Giuliano, Zanetti, Orazio, Frisoni, Giovanni Battista
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4051815/
https://ncbi.nlm.nih.gov/pubmed/24940065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S64015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars